CAPR beat EPS expectations by 40.43%
Mar 19, 2025, 10:31 PM
0.00%
What does CAPR do
Capricor Therapeutics, based in Beverly Hills, develops biological therapies for serious medical conditions, focusing on CAP-1002 for Duchenne muscular dystrophy in Phase 3 trials. The company also utilizes exosome technology for various therapeutic applications.
Capricor Therapeutics (CAPR) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Capricor Therapeutics's actual EPS was -$0.16, beating the estimate of -$0.27 per share, resulting in a 40.43% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.